Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...